Aalders JG - Search Results

1

Kinetic modeling and efficacy of intraperitoneal paclitaxel combined with intravenous cyclophosphamide and carboplatin as first-line treatment in ovarian cancer.

Hofstra LS, Bos AM, de Vries EG, van der Zee AG, Willemsen AT, Rosing H, Beijnen JH, Mulder NH, Aalders JG, Willemse PH. Hofstra LS, et al. Among authors: aalders jg. Gynecol Oncol. 2002 Jun;85(3):517-23. doi: 10.1006/gyno.2002.6665. Gynecol Oncol. 2002. PMID: 12051884

2

CA-125 in ovarian cancer: relation between half-life, doubling time and survival.

Willemse PH, Aalders JG, de Bruyn HW, Mulder NH, Sleijfer DT, de Vries EG. Willemse PH, et al. Among authors: aalders jg. Eur J Cancer. 1991;27(8):993-5. doi: 10.1016/0277-5379(91)90266-g. Eur J Cancer. 1991. PMID: 1832911

3

Risks and benefits of cisplatin in ovarian cancer. A quality-adjusted survival analysis.

Willemse PH, van Lith J, Mulder NH, Aalders JG, Bouma J, de Vries EG, Sleijfer DT. Willemse PH, et al. Among authors: aalders jg. Eur J Cancer. 1990 Mar;26(3):345-52. doi: 10.1016/0277-5379(90)90232-i. Eur J Cancer. 1990. PMID: 2141492

4

Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer.

Willemse PH, de Vries EG, Mulder NH, Aalders JG, Bouma J, Sleijfer DT. Willemse PH, et al. Among authors: aalders jg. Eur J Cancer. 1990 Mar;26(3):353-8. doi: 10.1016/0277-5379(90)90233-j. Eur J Cancer. 1990. PMID: 2141493

5

Long-term survival after vinblastine, bleomycin, and cisplatin treatment in patients with germ cell tumors of the ovary: an update.

Willemse PH, Aalders JG, Bouma J, Mulder NH, Verschueren RC, de Vries EG, Sleijfer DT. Willemse PH, et al. Among authors: aalders jg. Gynecol Oncol. 1987 Nov;28(3):268-77. doi: 10.1016/0090-8258(87)90172-7. Gynecol Oncol. 1987. PMID: 2445635

6

High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer.

Mulder PO, Willemse PH, Aalders JG, de Vries EG, Sleijfer DT, Sibinga CT, Mulder NH. Mulder PO, et al. Among authors: aalders jg. Eur J Cancer Clin Oncol. 1989 Apr;25(4):645-9. doi: 10.1016/0277-5379(89)90199-5. Eur J Cancer Clin Oncol. 1989. PMID: 2653845

7

Role of an early second-look laparotomy in ovarian cancer.

van Lith JM, Bouma J, Aalders JG, Boonstra H, Sleijfer DT, Willemse PH. van Lith JM, et al. Among authors: aalders jg. Gynecol Oncol. 1989 Nov;35(2):255-8. doi: 10.1016/0090-8258(89)90055-3. Gynecol Oncol. 1989. PMID: 2807020

8

Cell biological markers of drug resistance in ovarian carcinoma.

van der Zee AG, Hollema HH, de Bruijn HW, Willemse PH, Boonstra H, Mulder NH, Aalders JG, de Vries EG. van der Zee AG, et al. Among authors: aalders jg. Gynecol Oncol. 1995 Aug;58(2):165-78. doi: 10.1006/gyno.1995.1205. Gynecol Oncol. 1995. PMID: 7622101 Review.

9

Recombinant human interleukin-3 to dose-intensify carboplatin and cyclophosphamide chemotherapy in epithelial ovarian cancer: a phase I trial.

Veldhuis GJ, Willemse PH, van Gameren MM, Aalders JG, Mulder NH, Mull B, Biesma B, de Vries EG. Veldhuis GJ, et al. Among authors: aalders jg. J Clin Oncol. 1995 Mar;13(3):733-40. doi: 10.1200/JCO.1995.13.3.733. J Clin Oncol. 1995. PMID: 7884433 Clinical Trial.

10

Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.

Engelen MJ, de Bruijn HW, Hollema H, ten Hoor KA, Willemse PH, Aalders JG, van der Zee AG. Engelen MJ, et al. Among authors: aalders jg. Gynecol Oncol. 2000 Jul;78(1):16-20. doi: 10.1006/gyno.2000.5811. Gynecol Oncol. 2000. PMID: 10873403

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

81 results

Search Page

Filters